Mitral Valve Replacements Under On-Pump Beating Heart and Lung Perfusion/Ventilation Using a Minithoracotomy: An Experience with 11 Cases
DOI:
https://doi.org/10.1532/HSF98.20121013Abstract
Background: The primary aims of minimally-invasive cardiac valve surgery are to lessen the impact of the incision, extracorporeal circulation, myocardial ischemia, and pulmonary ischemia, to obtain satisfactory therapeutic results, and to allow a quicker rehabilitation. In this study, the feasibility of minimally-invasive mitral valve replacements without ascending aorta and vena cava cross-clamping under beating heart was evaluated by surveying 11 patients.
Methods: Preoperative risk factors, intraoperative techniques, and postoperative complications were surveyed and evaluated for one year (April 1, 2009 to March 30, 2010) in 11 patients who had undergone beating-heart mitral valve replacement surgery at The People's Hospital of Guangxi Zhuang Autonomous Region. Minithoracotomy and femoral arterial cannulation procedures were used in the surgeries for cardiopulmonary bypass (CPB) without ascending aorta and vena cava cross-clamping.
Results: The operations were performed successfully in all 11 patients. The CPB time was 52.80 ± 11.36 minutes; the mean postoperative mechanical ventilation assistance time was 8.20 ± 2.84 hours; and the mean transfusion volume of red cells was 2.20 ± 1.04 units. There were no cerebral complications, no periprosthetic leakage, no occurrence of permanent high-degree atrioventricular blockage, and no mortality.
Conclusion: Mitral valve replacement on the beating heart using a minithoracotomy and femoral arterial cannulation for CPB without ascending aorta and vena cava crossclamping under pulmonary ventilation is feasible. A larger number of patients are required to further characterize the efficacy and safety of this procedure.
References
Friedman M, Sellke FW, Wang SY, Weintraub RM, Johnson RG. 1994. Parameters of pulmonary injury after total or partial cardiopulmonary bypass. Circulation 90:262-8.nGologorsky E, Macedo FI, Salerno TA. 2011. Beating heart valve surgery with lung perfusion/ventilation during cardiopulmonary bypass: do we need to break the limits? Expert Rev Cardiovasc Ther 9:927-37.nHewson JR, Shaw M. 1983. Continuous airway pressure with oxygen minimizes the metabolic lesion of "pump lung." Can Anaesth Soc J 30:37-47.nHui H, Wei H, Tangwei L, et al. 2001. Aortic and mitral valve replacement with retrograde perfusion in the beating heart. Chin Med J (Engl) 114:1180-3.nLiebold A, Keyl C, Birnbaum DE. 1999. The heart produces but the lungs consume proinflammatory cytokines following cardiopulmonary bypass. Eur J Cardiothorac Surg 15:340-5.nLiu Y, Wang Q, Zhu X, et al. 2000. Pulmonary artery perfusion with protective solution reduces lung injury after cardiopulmonary bypass. Ann Thorac Surg 69:1402-7.nMacedo FI, Gologorsky E, Salerno TA. 2011. Beating-heart valve surgery: is the introduction of lung perfusion/ventilation the next step? Future Cardiol 7:61-7.nMassoudy P, Piotrowski JA, van de Wal HC, et al. 2003. Perfusing and ventilating the patient's lungs during bypass ameliorates the increase in extravascular thermal volume after coronary bypass grafting. Ann Thorac Surg 76:516-21; discussion 521-2.nMo A, Lin H, He W, Feng X. 2005. Clinical research of lung protection in heart surgery on beating heart and mild hypothermia CBP. Guangxi Med J 27:795-8.nMo A, Lin H, Wen Z, Lu W, Long X, Zhou Y. 2008. Efficacy and safety of on-pump beating heart surgery. Ann Thorac Surg 86:1914-8.nRichter JA, Meisner H, Tassani P, Barankay A, Dietrich W, Braun SL. 2000. Drew-Anderson technique attenuates systemic inflammatory response syndrome and improves respiratory function after coronary artery bypass grafting. Ann Thorac Surg 69:77-83.nSiepe M, Goebel U, Mecklenburg A, et al. 2008. Pulsatile pulmonary perfusion during cardiopulmonary bypass reduces the pulmonary inflammatory response. Ann Thorac Surg 86:115-22.nSievers HH, Freund-Kaas C, Eleftheriadis S, et al. 2002. Lung protection during total cardiopulmonary bypass by isolated lung perfusion: preliminary results of a novel perfusion strategy. Ann Thorac Surg 74:1167-72; discussion 1172.nSuzuki T, Fukuda T, Inoue Y, Aki A, Cho Y. 1997. Effectiveness of continuous pulmonary perfusion during total cardiopulmonary bypass to prevent lung reperfusion injury. Nippon Kyobu Geka Gakkai Zasshi 45:31-6.nSuzuki T, Fukuda T, Ito T, Inoue Y, Cho Y, Kashima I. 2000. Continuous pulmonary perfusion during cardiopulmonary bypass prevents lung injury in infants. Ann Thorac Surg 69:602-6.nSuzuki T, Ito T, Kashima I, Teruya K, Fukuda T. 2001. Continuous perfusion of pulmonary arteries during total cardiopulmonary bypass favorably affects levels of circulating adhesion molecules and lung function. J Thorac Cardiovasc Surg 122:242-8.nTütün U, Parlar AI, Altinay L, et al. 2011. Does on-pump normothermic beating-heart valve surgery with low tidal volume ventilation protect the lungs? Heart Surg Forum 14:E297-301.nWan S, DeSmet JM, Barvais L, Goldstein M, Vincent JL, LeClerc JL. 1996. Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 112:806-11.nWang J, Liu H, Salerno TA, et al. 2009. Alternate antegrade/retrograde perfusion: an effective technique to preserve hypertrophied hearts during valvular surgery. Eur J Cardiothorac Surg 35:69-76.nWang J, Liu H, Xiang B, et al. 2006. Keeping the heart empty and beating improves preservation of hypertrophied hearts for valve surgery. J Thorac Cardiovasc Surg 132:1314-20.nZheng JH, Xu ZW, Wang W, et al. 2004. Lung perfusion with oxygenated blood during aortic clamping prevents lung injury. Asian Cardiovasc Thorac Ann 12:58-60.n
Published
How to Cite
Issue
Section
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).
